BOSTON, May 15, 2015 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced it has been named to CNBC's elite Disruptor 50 list, one of only two biopharmaceutical companies to be named to the list. The Company is being recognized for its innovative late-stage investigational drug/device combination, ITCA 650, a matchstick-sized mini-pump designed to deliver up to a one-year supply of the commonly prescribed drug exenatide. (Exenatide is already commercially available as an injectable form for the treatment of type 2 diabetes.) ITCA 650 has successfully completed two phase 3 clinical trials, and full data from these studies will be presented at the 75th Scientific Sessions of the American Diabetes Association taking place in Boston June 5th through June 9th.
In recognition of its selection to the list, Intarcia's Chairman, President and CEO Kurt Graves was interviewed on Jim Cramer's Mad Money program. Full video of the interview can be accessed here. The host Jim Cramer concluded at the end of the interview by speculating that Intarcia's convergence of medicine and technology could "Up-end everything...but that's what a disruptor does...this turns the whole industry upside down."
This is CNBC's third annual Disruptor 50 list, which features private companies in 16 industries whose innovations are revolutionizing the business landscape. CNBC described the list this way: "These forward-thinking upstarts have identified unexploited niches in the marketplace that have the potential to become billion-dollar businesses, and they rushed to fill them. In the process, they are creating new ecosystems for their products and services. Unseating corporate giants is no easy feat...but we ranked those venture capital-backed companies doing the best job. Already it's hard to think of the world without them."
Mr. Graves commented on the achievement: "In our business, we believe value creation is fundamentally driven by one thing over time: having the very best people who stay laser-focused on the innovation and world-class execution needed to bring important new medicines to market. We are honored to be recognized for our efforts and continue to be driven to advance innovations that significantly improve patients' lives. This sort of recognition provides us an important external proof point that others see us accomplishing what our vision and values call for us to do, and that is very gratifying and reassuring. But be assured, it only makes us work harder to achieve progress for patients, providers and payors."
About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is an independent, privately held, biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. Delivering medicines just once or twice yearly has the potential to ensure improved patient adherence and compliance, which is otherwise difficult to achieve in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above-body temperature and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platform. Intarcia is conducting a phase 3 development program for type 2 diabetes that consists of four separate clinical trials, two of which have been completed. Intarcia continues to conduct research and development, utilizing its platform technology, to treat other chronic serious disorders in the field of diabetes, obesity and autoimmune diseases. For more information on Intarcia, please visit www.intarcia.com.
About ITCA 650
ITCA 650 (a once- or twice-yearly continuous subcutaneous delivery of exenatide) is being developed for the treatment of type 2 diabetes. The investigational therapy employs Intarcia's proprietary technology platform involving a matchstick-size, miniature osmotic pump that is placed sub-dermally to provide continuous and consistent drug therapy, and the company's proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for extended periods of time. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. Upon approval, ITCA 650 would represent the first injection-free GLP-1 therapy that can deliver up to a full year of treatment from a single placement. ITCA 650 is currently in a global phase 3 clinical trial program called FREEDOM.
Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc.
SOURCE Intarcia Therapeutics, Inc.